Borderline personality disorder. Overview of biologic factors.
Exploring the biology of neurotransmitters and polymorphic genes that influence behavior most certainly will increase understanding of the complexity of personality disorders and the people who suffer with them. Continuing biologic exploration of the personality disorders will also provide new and valuable information that will inform and direct ever more sophisticated and specific psychiatric treatments. Further, it will supply knowledge that might begin to erode the strong biases and negative labels that have for too long been applied to these patients. These labels may have been applied not because these patients are bad people, but because of ignorance in understanding their complexity and limited ability to improve their condition. Nonetheless, clinicians must refrain from concluding that the answers to all problems in psychiatric treatment can be answered by the molecular geneticist or biologic researcher. As Reiss et al have written when speaking about nonshared environmental effects and its role in the development of psychopathology: "Psychiatry has been forced into the chronically uncomfortable position of straddling biomedicine and the social sciences and seems always to hunger for relief.... [Yet] the data simply do not permit a conception of the future centered on a straightforward biomedical answer to the fundamental question of the pathogenesis of major disorders. Indeed, a balanced image of the future contains a growing and equal partnership of the social sciences and molecular biology."
Silk
K R
KR
Department of Psychiatry, University of Michigan Health System, Ann Arbor, USA. ksilk@umich.edu
D001883:Borderline Personality Disorder / Q000378:metabolism; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D015928:Cognitive Behavioral Therapy; D020022:Genetic Predisposition to Disease; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010554:Personality Disorders / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D011619:Psychotropic Drugs / Q000627:therapeutic use
D018377:Neurotransmitter Agents; D011619:Psychotropic Drugs